Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeurogesX has submitted an investigational new drug application to the FDA for the clinical development of NGX-1998, the company's product candidate utilizing a high-concentration liquid formulation of capsaicin.
Subscribe to our email newsletter
The company further announced that the investigational new drug (IND) is now effective and that it may commence clinical studies under this IND. With the new investigational new drug application in place, NeurogesX intends to initiate a Phase I clinical IND in 2008 to evaluate potential controls for studies in peripheral neuropathic pain.
Anthony DiTonno, president and CEO, said: “NGX-1998 contains the same active ingredient as our lead product candidate, NGX-4010, but its proprietary liquid formulation is designed to enable rapid delivery of capsaicin into the skin. In doing so, we believe that NGX-1998 offers the potential for short treatment times and the potential for expanding the addressable market of our capsaicin based product candidate pipeline.”